The kyphoplasty market size was valued at USD 692.78 million in 2025 and is estimated to grow from USD 732.61 million in 2026 to reach USD 968.89 million by 2031, at a CAGR of 5.75% during the forecast period (2026-2031). This report is Segmented by Product Type (Balloon Catheters, Bone Access Devices, Bone Cement, Cement Mixing Systems, Instruments, Others), Indication (Osteoporotic, Neoplastic, Traumatic VCF, Others), End User (Hospitals, Ascs, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Kyphoplasty Instruments are projected to grow at a 6.10% CAGR from 2026 to 2031, driven by the increasing adoption of navigation and robotic guidance in pedicle access workflows. A 2025 study highlighted that robot-assisted percutaneous kyphoplasty reduced fluoroscopy counts to 6.8 per procedure compared to the conventional average of 39.4. Bone access devices are advancing, particularly for challenging thoracic anatomy, while accessories like biopsy tools are gaining relevance as oncology care integrates ablation and augmentation workflows. This shift favors companies offering integrated procedure kits over standalone components.
Europe is the second-largest regional cluster in the kyphoplasty market, with Germany, the U.K., France, Italy, and Spain forming the core procedure base. Germany’s improved reimbursement and coding processes are aiding hospitals in capturing claims more consistently. Clinical evidence highlights the need for timely intervention, as an initial vertebral fracture increases the risk of subsequent fractures within two years. However, reimbursement parity between kyphoplasty and vertebroplasty in parts of Southern Europe limits the premium positioning of balloon-based systems.
Asia-Pacific is the fastest-growing region in the kyphoplasty market, projected to expand at a 7.88% CAGR through 2031. Japan’s 2025 insurance expansion for treating multiple vertebral bodies in one session is expected to improve per-patient economics and reduce repeat admissions. India benefits from the growth of private tertiary care hospitals, while South Korea strengthens its position with established spine surgery training programs. The Middle East, Africa, and South America remain in early stages, with volumes concentrated in GCC hospital systems and Brazil’s private hospitals, where adoption depends on trained surgeons and manufacturer-backed education programs.
Global Kyphoplasty Market Trends and Insights
Rising Osteoporotic Vertebral Compression Fracture Burden
The kyphoplasty market's primary demand is closely tied to the global surge in osteoporotic vertebral compression fractures. A 2025 study forecasted that as the global population ages and preventive measures lag, the prevalence of spinal fractures could jump from 65.2 per 100,000 in 2025 to 128.04 per 100,000 by 2050. In the U.S., nearly 750,000 new cases of osteoporotic vertebral compression fractures emerge annually. The U.K. sees close to 120,000 cases each year, with women aged 85-89 experiencing an incidence rate eight times that of their 60-64 counterparts. Many vertebral fractures initially go unnoticed, limiting conservative care options and increasing the likelihood of surgical intervention after a secondary collapse.Adoption of Minimally Invasive Spine Procedures
The kyphoplasty market is benefiting from the shift of spine procedures to minimally invasive and outpatient settings. In 2025, CMS finalized a 2.9% update to the ambulatory surgery center payment rate, leading to total ASC payments nearing USD 7.4 billion. This transition supports moving vertebral augmentation from inpatient to outpatient settings. ASC-based procedures favor compact systems, simplified handling, and single-use cement kits, influencing purchasing behaviors in the kyphoplasty market. A 2025 study highlighted that robot-assisted percutaneous kyphoplasty, performed under local anesthesia in a day-surgery setting, resulted in a mean hospital stay of 34 hours, with no 30-day readmissions. Manufacturers offering comprehensive outpatient kits and digital workflow tools are well-positioned as the market increasingly adopts same-day care models.Reimbursement Scrutiny and Coverage Variability
Reimbursement pressures remain a significant challenge for the kyphoplasty market in North America. The CMS CMMI WISeR Model, effective January 1, 2026, introduced prior authorization and pre-payment medical reviews for kyphoplasty and vertebroplasty in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. These states, with substantial Medicare-age populations, represent a critical portion of the U.S. market. The stricter documentation requirements under this model reduce flexibility for community-based kyphoplasty and may influence payer behavior beyond the pilot states. In Europe, reimbursement parity between kyphoplasty and vertebroplasty in parts of Spain and Italy limits premium pricing, pushing manufacturers to rely more on health economic evidence and real-world data.Other drivers and restraints analyzed in the detailed report include:
- Better Vertebral Height Restoration Versus Vertebroplasty
- Expanded Use in Malignancy-Related Vertebral Fractures
- Cement Leakage and Revision Risk Concerns
Segment Analysis
In 2025, Kyphoplasty Balloon Catheters accounted for 31.89% of the kyphoplasty market, maintaining their position as the leading product category. These catheters are essential for cavity creation in every procedure and benefit from single-use economics, ensuring a recurring revenue stream for manufacturers. Bone cement and cement mixing systems, while smaller individually, form a consumable chain that supports kit-level pricing and bundling strategies. Companies like Globus Medical and Medtronic exemplify this approach with integrated procedural systems.Kyphoplasty Instruments are projected to grow at a 6.10% CAGR from 2026 to 2031, driven by the increasing adoption of navigation and robotic guidance in pedicle access workflows. A 2025 study highlighted that robot-assisted percutaneous kyphoplasty reduced fluoroscopy counts to 6.8 per procedure compared to the conventional average of 39.4. Bone access devices are advancing, particularly for challenging thoracic anatomy, while accessories like biopsy tools are gaining relevance as oncology care integrates ablation and augmentation workflows. This shift favors companies offering integrated procedure kits over standalone components.
Complete Report Scope:
- By Product Type
- Kyphoplasty Balloon Catheters
- Kyphoplasty Bone Access Devices
- Kyphoplasty Bone Cement
- Kyphoplasty Cement Mixing Systems
- Kyphoplasty Instruments
- Others
- By Indication
- Osteoporotic Vertebral Compression Fractures
- Neoplastic Vertebral Compression Fractures
- Traumatic Vertebral Compression Fractures
- Other Vertebral Compression Fracture Indications
- By End User
- Hospitals
- Ambulatory Surgery Centers
- Specialty Clinics
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
In 2025, North America accounted for 38.95% of the kyphoplasty market share, maintaining its position as the largest regional base. The U.S. significantly contributed to this dominance, with nearly 750,000 new osteoporotic vertebral compression fractures annually and consistent procedure volumes supported by Medicare coverage under CPT codes 22513 to 22515. Despite the WISeR model introducing tighter review standards in select states in 2026, the region remains robust. Medtronic leads the market through its Kyphon brand, facing competition from other device manufacturers. Canada is progressing in outpatient migration, while Mexico, though underpenetrated, is gaining relevance as private hospitals invest in minimally invasive spine capabilities.Europe is the second-largest regional cluster in the kyphoplasty market, with Germany, the U.K., France, Italy, and Spain forming the core procedure base. Germany’s improved reimbursement and coding processes are aiding hospitals in capturing claims more consistently. Clinical evidence highlights the need for timely intervention, as an initial vertebral fracture increases the risk of subsequent fractures within two years. However, reimbursement parity between kyphoplasty and vertebroplasty in parts of Southern Europe limits the premium positioning of balloon-based systems.
Asia-Pacific is the fastest-growing region in the kyphoplasty market, projected to expand at a 7.88% CAGR through 2031. Japan’s 2025 insurance expansion for treating multiple vertebral bodies in one session is expected to improve per-patient economics and reduce repeat admissions. India benefits from the growth of private tertiary care hospitals, while South Korea strengthens its position with established spine surgery training programs. The Middle East, Africa, and South America remain in early stages, with volumes concentrated in GCC hospital systems and Brazil’s private hospitals, where adoption depends on trained surgeons and manufacturer-backed education programs.
List of Companies Covered in this Report:
- ATEC Spine
- Benvenue Medical, Inc.
- Biopsybell S.r.l.
- Cardinal Health
- Cook Group
- G-21 S.r.l.
- Globus Medical
- ICU Medical
- Johnson & Johnson
- Joline GmbH and Co. KG
- Medtronic
- Merit Medical Systems
- Orthofix
- Osseon Therapeutics, Inc.
- PanMed US, LLC
- Spine Wave
- Stryker
- Teknimed SAS
- Zavation Medical Products, LLC
- Zimmer Biomet
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alphatec Holdings, Inc.
- Benvenue Medical, Inc.
- Biopsybell S.r.l.
- Cardinal Health, Inc.
- Cook Medical LLC
- G-21 S.r.l.
- Globus Medical, Inc.
- ICU Medical, Inc.
- Johnson and Johnson Services, Inc.
- Joline GmbH and Co. KG
- Medtronic plc
- Merit Medical Systems, Inc.
- Orthofix Medical Inc.
- Osseon Therapeutics, Inc.
- PanMed US, LLC
- Spine Wave, Inc.
- Stryker Corporation
- Teknimed SAS
- Zavation Medical Products, LLC
- Zimmer Biomet Holdings, Inc.
